ReviewClinical and translational allergy2017
Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews.
Review in Clinical and translational allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Sublingual immunotherapy for asthma.The Cochrane database of systematic reviews · 2020Pooled it
- Using Biologics in the Prevention of Anaphylaxis.Current allergy and asthma reports · 2025Review
- Asthma and stem cell therapy.World journal of stem cells · 2025Review
- Allergen immunotherapy in Italy: How, when, and why-A real-world study conducted through a patient association.The World Allergy Organization journal · 2025Article
- Comparison of allergen immunotherapy practice patterns in inhalant allergies in the United States of America and Europe: Similarities and differences 2023.The World Allergy Organization journal · 2023Review
- Effectiveness of sublingual immunotherapy with house dust mite drops in asthmatic children at different ages.Frontiers in pediatrics · 2023Article
- Review
- Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model.Clinical and translational allergy · 2022Article
- Article
- Pterostilbene suppresses oxidative stress and allergic airway inflammation through AMPK/Sirt1 and Nrf2/HO-1 pathways.Immunity, inflammation and disease · 2021Article
- Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis.Clinical and translational allergy · 2021Article
- Benefit Effect of Sublingual Dust Mite Drops on the Control of Asthma in Children.International journal of general medicine · 2021Article
- Effect ofAllergy, asthma & immunology research · 2020Article
- Allergen Immunotherapy in Pediatric Asthma: A Pragmatic Point of View.Children (Basel, Switzerland) · 2020Review
- Allergic Endotypes and Phenotypes of Asthma.The journal of allergy and clinical immunology. In practice · 2020Article
- The Possible Dual Role of the ACE2 Receptor in Asthma and Coronavirus (SARS-CoV2) Infection.Frontiers in cellular and infection microbiology · 2020Review
- Efficacy of Allergen Immunotherapy for Allergic Asthma in Real World Practice.Allergy, asthma & immunology research · 2020Article
- Resolution of allergic asthma.Seminars in immunopathology · 2019Review
- Retrospective analysis of aeroallergen's sensitization patterns in Edmonton, Canada.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2019Article
- Novel therapeutic targets for allergic airway disease in children.Drugs in context · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 13 institutions in 9 countries.
Funding
Abstract
backgroundThere is clinical uncertainty about the effectiveness and safety of allergen immunotherapy (AIT) for the treatment of allergic asthma.
objectivesTo undertake a systematic overview of the effectiveness, cost-effectiveness and safety of AIT for the treatment of allergic asthma.
methodsWe searched nine electronic databases from inception to October 31, 2015. Systematic reviews were independently screened by two reviewers against pre-defined eligibility criteria and critically appraised using the Critical Appraisal Skills Programme quality assessment tool for systematic reviews. Data were descriptively and thematically synthesized.
resultsWe identified nine eligible systematic reviews; these focused on delivery of AIT through the following routes: subcutaneous (SCIT; n = 3); sublingual (SLIT; n = 4); and both SCIT and SLIT (n = 2). This evidence found that AIT delivered by SCIT and SLIT can improve medication and symptom scores and measures of bronchial hyper-reactivity. The impact on measures of lung function or asthma control was however less clear. We found no systematic review level evidence on the cost-effectiveness of SCIT or SLIT. SLIT had a favorable safety profile when compared to SCIT, particularly in relation to the risk of systemic reactions.
conclusionsAIT has the potential to achieve reductions in symptom and medication scores, but there is no clear or consistent evidence that measures of lung function can be improved. Bearing in mind the limitations of synthesizing evidence from systematic reviews and the fact that these reviews include mainly dated studies, a systematic review of current primary studies is now needed to update this evidence base, estimate the effectiveness of AIT on asthma outcomes and to investigate the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.